Comments on: Novartis Kisqali® shows deepening benefit in new analysis, reducing the risk of recurrence by 28.5% in a broad population of patients with early breast cancer

Comments on: Novartis Kisqali® shows deepening benefit in new analysis, reducing the risk of recurrence by 28.5% in a broad population of patients with early breast cancer https://thegbm.com/novartis-kisqali-shows-deepening-benefit-in-new-analysis-reducing-the-risk-of-recurrence-by-28-5-in-a-broad-population-of-patients-with-early-breast-cancer/ Business news, opinion, reviews, interviews Mon, 16 Sep 2024 08:15:00 +0000 hourly 1 https://wordpress.org/?v=6.6.2